🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against superbug strains of the bacteria, according to researchers.

A Worldwide Health Concern

The sexually transmitted infection are escalating worldwide, with estimates suggesting over 82 million instances per year. Particularly high rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the context of rising global incidence, the spread of superbugs and the extremely scarce available drugs presently on offer.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The World Health Organization has designated it as a "critical concern". Recent surveillance found that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Clearance

Zoliflodacin, alternatively called a brand name, was cleared by the US FDA in recent days for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This medication, which is employed against urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin stemmed from a innovative non-profit model for medication research. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval signifies a huge turning point in the management of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Testing Results and Global Access

According to data detailed in a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the current standard treatment, which involves an injection and a pill. The research included nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the ability to register and commercialise the drug in numerous regions with limited resources.

Medical professionals on the front lines have expressed hope. Having a easy-to-administer therapy of this kind is seen as a "game-changer" for gonorrhoea control. This is deemed vital to lessen the impact of the infection for people and to stop the proliferation of untreatable gonorrhoea worldwide.